Free Trial

Vega Investment Solutions Makes New $720,000 Investment in Zoetis Inc. (NYSE:ZTS)

Zoetis logo with Medical background

Vega Investment Solutions purchased a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,418 shares of the company's stock, valued at approximately $720,000.

Several other hedge funds have also added to or reduced their stakes in ZTS. Mission Wealth Management LP raised its position in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. raised its position in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after purchasing an additional 62 shares during the period. HUB Investment Partners LLC raised its position in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the period. Coppell Advisory Solutions LLC raised its position in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares during the period. Finally, Deseret Mutual Benefit Administrators raised its position in shares of Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after purchasing an additional 65 shares during the period. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company's stock.

Zoetis Stock Performance

ZTS opened at $162.10 on Friday. The stock has a market capitalization of $72.17 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 2.78 and a beta of 0.94. The company has a fifty day moving average of $156.51 and a 200 day moving average of $164.96. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same period last year, the company posted $1.38 EPS. The business's revenue was up 1.4% on a year-over-year basis. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. Zoetis's payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Finally, UBS Group cut their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of "Buy" and an average price target of $212.75.

Check Out Our Latest Stock Report on Zoetis

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zoetis Right Now?

Before you consider Zoetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.

While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock
The Hottest AI Stock You Haven’t Bought Yet

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines